Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 3
1986 2
1987 2
1988 1
1989 3
1990 4
1992 5
1993 4
1994 1
1995 2
1997 2
1999 1
2000 3
2001 5
2002 5
2003 12
2004 10
2005 10
2006 13
2007 6
2008 14
2009 14
2010 8
2011 13
2012 18
2013 23
2014 22
2015 32
2016 34
2017 34
2018 38
2019 50
2020 45
2021 36
Text availability
Article attribute
Article type
Publication date

Search Results

452 results
Results by year
Filters applied: . Clear all
Page 1
Mir20a/106a-WTX axis regulates RhoGDIa/CDC42 signaling and colon cancer progression.
Zhu GF, Xu YW, Li J, Niu HL, Ma WX, Xu J, Zhou PR, Liu X, Ye DL, Liu XR, Yan T, Zhai WK, Xu ZJ, Liu C, Wang L, Wang H, Luo JM, Liu L, Li XQ, Guo S, Jiang HP, Shen P, Lin HK, Yu DH, Ding YQ, Zhang QL. Zhu GF, et al. Among authors: xu zj. Nat Commun. 2019 Jan 10;10(1):112. doi: 10.1038/s41467-018-07998-x. Nat Commun. 2019. PMID: 30631060 Free PMC article.
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, Li YP, Wu WC, Xu ZJ, Muccino DR, Ford AP; Protocol 012 Investigators. Smith JA, et al. Among authors: xu zj. Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25. Lancet Respir Med. 2020. PMID: 32109425 Clinical Trial.
Gefapixant in two randomised dose-escalation studies in chronic cough.
Smith JA, Kitt MM, Butera P, Smith SA, Li Y, Xu ZJ, Holt K, Sen S, Sher MR, Ford AP. Smith JA, et al. Among authors: xu zj. Eur Respir J. 2020 Mar 20;55(3):1901615. doi: 10.1183/13993003.01615-2019. Print 2020 Mar. Eur Respir J. 2020. PMID: 31949115
452 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page